Pharming Group Stock

Pharming Group Debt 2024

Pharming Group Debt

110.03 USD

Ticker

PHARM.AS

ISIN

NL0010391025

WKN

A1H65A

In 2024, Pharming Group's total debt was 110.03 USD, a -370.68% change from the -40.65 USD total debt recorded in the previous year.

Pharming Group Aktienanalyse

What does Pharming Group do?

Pharming Group NV was founded in 1988 and is headquartered in the Netherlands. The company specializes in the development and marketing of medical products for the treatment of rare diseases. Its business model is based on the discovery and development of recombinant proteins. These proteins are produced using genetic engineering techniques and serve as the foundation for the development of therapeutic products in various areas. The main focus of Pharming Group NV is the manufacturing and marketing of biopharmaceuticals. The company has a wide range of products used in the treatment of rare diseases, including C1-esterase inhibitor preparations used for acute attacks in hereditary angioedema. Another important product of Pharming Group NV is recombinant human lysozyme. It is used in the treatment of cystic fibrosis and has shown promising results as a therapeutic approach. Pharming Group NV also collaborates closely with various research and development organizations to develop new products and expand knowledge in the medical industry. The company has experienced impressive growth in recent years. In 2019, Pharming Group NV achieved a revenue of 149 million euros. A significant portion of this revenue was generated through the sale of C1-esterase inhibitor preparations. Pharming Group NV has also made a name for itself in the international market. The company has branches in the USA and Europe and works closely with international regulatory authorities to ensure smooth approval and marketing of its products. Overall, Pharming Group NV has a promising future as it continues to invest in research, development, and expansion of its product portfolio. By focusing on the development of products for the treatment of rare diseases, Pharming Group NV positions itself as a leading company in the medical industry and contributes to improving the lives of people worldwide. Pharming Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Pharming Group's Debt Structure

Pharming Group's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Pharming Group's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Pharming Group’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Pharming Group’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Pharming Group stock

What is the debt of Pharming Group this year?

Pharming Group has a debt level of 110.03 USD this year.

What was the debt of Pharming Group compared to the previous year?

The debt of Pharming Group has increased by -370.68% compared to the previous year dropped.

What are the consequences of high debt for investors in Pharming Group?

High debt can pose a risk for investors of Pharming Group, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Pharming Group?

Low debt means that Pharming Group has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Pharming Group affect the company?

An increase in debt of Pharming Group can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Pharming Group affect the company?

A reduction in debt of Pharming Group can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Pharming Group?

Some factors that can influence the debt of Pharming Group include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Pharming Group so important for investors?

The debts of Pharming Group are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Pharming Group take to change the debt?

To change the debt, Pharming Group can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Pharming Group pay?

Over the past 12 months, Pharming Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pharming Group is expected to pay a dividend of 0 USD.

What is the dividend yield of Pharming Group?

The current dividend yield of Pharming Group is .

When does Pharming Group pay dividends?

Pharming Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pharming Group?

Pharming Group paid dividends every year for the past 0 years.

What is the dividend of Pharming Group?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pharming Group located?

Pharming Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pharming Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pharming Group from 12/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.

When did Pharming Group pay the last dividend?

The last dividend was paid out on 12/18/2024.

What was the dividend of Pharming Group in the year 2023?

In the year 2023, Pharming Group distributed 0 USD as dividends.

In which currency does Pharming Group pay out the dividend?

The dividends of Pharming Group are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Pharming Group stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Pharming Group

Our stock analysis for Pharming Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharming Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.